Early Breast Cancer - Neoadjuvant Treatment
-
Breast Cancer
Early Breast Cancer - Neoadjuvant Treatment
-
Pre-malignant lesions
-
VICC-DTBRE23082
Ductal Cancer in Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Tx
-
-
BRACA 1/2
-
ER/PR+
-
Premenopausal
-
Stage II/III Pre or Post menopausal
-
Lobular
-
VICC-NCBRE23172
Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
-
-
-
HER2+
-
Stage II
-
Stage 1
-
VICCBRE2241
PhII TPIV100/Placebo & Sargramostim for Tx of HER2+ Stage II-III BC in Pts w/Res Dis Aft Chemo/Surg
-
-
VICCBRE2241
PhII TPIV100/Placebo & Sargramostim for Tx of HER2+ Stage II-III BC in Pts w/Res Dis Aft Chemo/Surg
-
-
Stage III
-
VICCBRE2241
PhII TPIV100/Placebo & Sargramostim for Tx of HER2+ Stage II-III BC in Pts w/Res Dis Aft Chemo/Surg
-
-
-
Stage II/III TNBC
-
VICC-VCBRE23490
Phase II Neoadjuvant Trial of Darolutamide in Early-Stage AR+ Triple-Negative Breast Cancer
-
-
TNBC
-
VICCBRE24564
Sac-TMT Followed by Carbo/Pacli v Chemo, Both in Combo w/Pembro in TNBC or HR-Low +/HER2- BC
-
For ER negative or ER-low (1+ in 10% of cells or less), IO eligible
T1c and node positive OR T2-4, node positive or negative
Includes inflammatory
No distant metastatic disease
Cannot be planned for adj CDK4/6 inhibitor (ER-low only)
-
-
-